Fudan University
复旦大学
Hospitals that carry this university's name, added together, plus papers and trials that name only the university.
Research activity, not treatment quality. Not medical advice. How this works
Nasopharyngeal carcinoma
鼻咽癌Led 80 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.4%).
- Open trials led
- 13
- Research papers it led
- 80
- Trials it led
- 44
- Share of China's trials
- 7.4%
- Share of the world's papers
- 2.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial.
- Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.
- LINC-PINT expression and rs1059698 polymorphism associate with chemoradiotherapy efficacy in Chinese nasopharyngeal carcinoma patients.
- Mucosal Flap Reconstruction Enhances Survival in Salvage Endoscopic Nasopharyngectomy for Recurrent Nasopharyngeal Carcinoma: A Propensity-Matched Cohort Study.
- Artificial intelligence-assisted detection of nasopharyngeal carcinoma on endoscopic images: a national, multicentre, model development and validation study.
Trials on ClinicalTrials.gov6
- Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma
- Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
- Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
- Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
- Adjuvant vs Surgery Only in Early-stage Recurrent NPC
- Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 109 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.9%).
- Open trials led
- 17
- Research papers it led
- 109
- Trials it led
- 53
- Share of China's trials
- 9.3%
- Share of the world's papers
- 2.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
- Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
- Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Cli
- Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma.
- Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring.
Trials on ClinicalTrials.gov6
- PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
- An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
- Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
- CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
- Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
- Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
Hepatocellular carcinoma
肝细胞癌Led 603 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (5.5%).
- Open trials led
- 20
- Research papers it led
- 603
- Trials it led
- 107
- Share of China's trials
- 7.3%
- Share of the world's papers
- 2.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
- External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial.
- 3D-CEUS/MRI-CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: a multicenter prospective study of therapeutic response evaluation.
- Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial.
- Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.
Trials on ClinicalTrials.gov6
- Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
- The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
- The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
Stomach cancer
胃癌Led 281 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (3.9%).
- Open trials led
- 39
- Research papers it led
- 281
- Trials it led
- 88
- Share of China's trials
- 6.0%
- Share of the world's papers
- 1.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).
- Nutritional support after hospital discharge reduces long-term mortality in patients after gastric cancer surgery: Secondary analysis of a prospective randomized trial.
- Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01).
- Early intravenous branched-chain amino acid-enriched nutrition supplementation in older patients undergoing gastric surgery: a randomized clinical trial.
- First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Trials on ClinicalTrials.gov6
- An Observational Study on Gastric Cancer in High-risk Individuals
- A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
- A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial
- Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
Hepatoblastoma
肝母细胞瘤Led 8 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.6%).
- Open trials led
- 0
- Research papers it led
- 8
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 1.8%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Nutritional status associated with clinical outcomes in children with solid tumors: A retrospective cohort study from China.
- Single-cell profiles delineate immune cell remodeling and enhanced tumor-fibroblast interaction of hepatoblastoma after chemotherapy.
- YAP-activated NAT10 promotes hepatoblastoma progression by activating the pentose phosphate pathway.
- ACSL4 promotes the formation of the proliferative subtype in hepatoblastoma.
- Global, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: a trend analysis.
Trials on ClinicalTrials.gov1
Retinoblastoma
视网膜母细胞瘤Led 7 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 3
- Research papers it led
- 7
- Trials it led
- 3
- Share of China's trials
- 23.1%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Role of additional topotecan injections (plus two) in reducing recurrence rate in retinoblastoma of group D and group E patients: a retrospective study.
- Assessment of Retinal Microvasculature and Choroidal Vascularity After Intra-arterial Chemotherapy for Retinoblastoma.
- Quantitative evaluation of retinal microvasculature and retrobulbar vessels after intravenous chemotherapy for retinoblastoma.
- Low expression of NR1D1 and NR2E3 is associated with advanced features of retinoblastoma.
- Multimodal Imaging of a Retinocytoma.
Trials on ClinicalTrials.gov4
- High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
- Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
- Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
- G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
Chordoma
脊索瘤Led 8 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.8%).
- Open trials led
- 0
- Research papers it led
- 8
- Trials it led
- 1
- Share of China's trials
- 16.7%
- Share of the world's papers
- 1.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Soft-tissue reconstruction with pedicled vertical rectus abdominis myocutaneous flap after total or high sacrectomy for giant sacral tumor.
- Primary Skull Base Chordomas: A Clinicopathological Analysis of 94 Patients.
- Association of radical vs palliative resection of spinal chordoma with survival: a population-based study.
- How I do it? Resection of residual petrous apex chordoma with combined endoscopic endonasal and contralateral transmaxillary approaches.
- Ubiquitin-independent pathway regulates the RIT1-MAPK pathway in chordoma progression.
Trials on ClinicalTrials.gov1
Osteosarcoma
骨肉瘤Led 26 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 26
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?
- Peri-osteosarcoma adipose computed tomography attenuation and volume for predicting chemotherapy response in pediatric patients.
- ENO1 promotes cancer metastasis via stimulating metabolism reprogramming in osteosarcoma.
- Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.
- Establishment and characterization of a patient-derived metastatic extraskeletal Ewing sarcoma cell line ES-ZSS-1.
Gastrointestinal stromal tumour
胃肠道间质瘤Led 30 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.3%).
- Open trials led
- 0
- Research papers it led
- 30
- Trials it led
- 1
- Share of China's trials
- 1.4%
- Share of the world's papers
- 1.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Endoscopic transmural route for dissection of gastric submucosal tumors with extraluminal growth: experience in two cases.
- Proteomic Characterization Identifies Clinically Relevant Subgroups of Gastrointestinal Stromal Tumors.
- Endoscopic resection for small rectal gastrointestinal stromal tumors: a pilot study.
- Hidden risk factors for recurrence of jejunoileal Gastrointestinal stromal tumors with low NIH classification: implications for surveillance and adjuvant therapy.
- A case of quadruple wild-type gastrointestinal stromal tumor with CDC42BPB::NTRK3 fusion and abundant lymphoid infiltration.
Trials on ClinicalTrials.gov6
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- RCT of EFTR Versus STER for GIST Treatment
- A Study of HQP1351 in Patients With GIST or Other Solid Tumors
- Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GIST
- Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST
- A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
Neuroblastoma
神经母细胞瘤Led 20 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 1
- Research papers it led
- 20
- Trials it led
- 1
- Share of China's trials
- 2.4%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Deep learning models for differentiating three sinonasal malignancies using multi-sequence MRI.
- The value of elective neck irradiation in management of esthesioneuroblastoma: a retrospective study based on propensity score matching.
- Survival Analysis and Prognostic Factors After Endonasal Resection of Advanced Olfactory Neuroblastomas: A Single Institution Experience.
- Nutritional status associated with clinical outcomes in children with solid tumors: A retrospective cohort study from China.
- Incidental Neuroblastoma.
Trials on ClinicalTrials.gov3
Ewing sarcoma
尤文肉瘤Led 8 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.6%).
- Open trials led
- 0
- Research papers it led
- 8
- Trials it led
- 2
- Share of China's trials
- 12.5%
- Share of the world's papers
- 0.7%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis ?
- Gene Fusions as Potential Therapeutic Targets in Soft Tissue Sarcomas.
- Establishment and characterization of a patient-derived metastatic extraskeletal Ewing sarcoma cell line ES-ZSS-1.
- Clinicopathological characteristics and genetic features of young and senior Ewing sarcoma patients.
- Gastrointestinal Ewing Sarcoma: A Clinicopathological and Molecular Genetic Analysis of 25 Cases.
Multiple myeloma
多发性骨髓瘤Led 37 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.8%).
- Open trials led
- 4
- Research papers it led
- 37
- Trials it led
- 5
- Share of China's trials
- 1.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Real-World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15-Year Period.
- Advantage of Tolerability following Arsenic Trioxide-VTD vs VRD in newly diagnosed multiple myeloma patients: a prospective, open-label study.
- Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.
- Enhanced clinical outcomes with radiotherapy in diagnostically challenging intracranial plasmacytomas: Analysis of 190 cases.
- IgE-kappa multiple myeloma with kappa free light chain: a case report.
Trials on ClinicalTrials.gov6
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- Longitudinal Data Registry of Plasma Cell Dyscrasia
- The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
B-cell acute lymphoblastic leukaemia (B-ALL)
B 细胞急性淋巴细胞白血病Led 0 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.9%).
- Open trials led
- 0
- Research papers it led
- 0
- Trials it led
- 1
- Share of China's trials
- 0.4%
- Share of the world's papers
- 0.0%
Trials on ClinicalTrials.gov6
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
- Phase Ib Clinical Study of Keynatinib
- Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Aplastic anaemia
再生障碍性贫血Led 3 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Mendelian randomization of circulating proteome identifies IFN-γ as a druggable target in aplastic anemia.
- Monocytic myeloid-derived suppressive cells mitigate over-adipogenesis of bone marrow microenvironment in aplastic anemia by inhibiting CD8+ T cells.
- Effects of cimetidine on ciclosporin population pharmacokinetics and initial dose optimization in aplastic anemia patients.
Haemophagocytic lymphohistiocytosis (HLH)
噬血细胞性淋巴组织细胞增生症Led 2 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.3%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 1
- Share of China's trials
- 2.1%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
Trials on ClinicalTrials.gov3
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Efficacy and Safety of Interferon-Gamma Monoclonal Antibody Combined With Dexamethasone in the Treatment of Refractory Adult Secondary Hemophagocytic Lymphohistiocytosis
- Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
Beta thalassaemia
β 地中海贫血Led 2 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.9%).
- Open trials led
- 1
- Research papers it led
- 2
- Trials it led
- 2
- Share of China's trials
- 4.3%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
Trials on ClinicalTrials.gov4
- A Long-term Follow-up Study in Participants Who Received CS-101
- Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major
- A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major
- A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major
Neuromyelitis optica spectrum disorder (NMOSD)
视神经脊髓炎谱系疾病Led 23 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.5%).
- Open trials led
- 1
- Research papers it led
- 23
- Trials it led
- 2
- Share of China's trials
- 2.6%
- Share of the world's papers
- 1.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
- Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.
- Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study.
- Eculizumab for the acute attack of neuromyelitis optica spectrum disorder.
- KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort.
Trials on ClinicalTrials.gov6
- HANDLE-a Real World Study on Satralizumab in NMOSD
- A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
- BLAZE-Limiting Approach in NMOSD
- A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
- An Open Label Study of the Effects of SHR1459 in NMOSDs Patients
IgG4-related disease
IgG4相关性疾病Led 6 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.1%).
- Open trials led
- 0
- Research papers it led
- 6
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Immunoglobulin G4-related sclerosing mastitis: MRI findings and the literature review.
- Clinical and pathological predictors of relapse in IgG4-related disease.
- Pathological count of IgG4-positive plasmacytes suggests extraophthalmic involvement and relapse in patients with IgG4-related ophthalmic disease: a retrospective study.
- Heart Transplantation for a Rare Case of Immunoglobulin G4-related Cardiac Pseudotumor.
- Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study.
Myasthenia gravis
重症肌无力Led 33 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.6%).
- Open trials led
- 5
- Research papers it led
- 33
- Trials it led
- 7
- Share of China's trials
- 7.6%
- Share of the world's papers
- 1.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis.
- Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.
- The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.
- Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study.
- Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.
Trials on ClinicalTrials.gov6
- EFG vs IVIG in TAMG
- An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- Myasthenia Gravis Registry in China
- Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
- Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
- An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
Moyamoya disease
烟雾病Led 24 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.9%).
- Open trials led
- 1
- Research papers it led
- 24
- Trials it led
- 3
- Share of China's trials
- 9.1%
- Share of the world's papers
- 1.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Inhalational versus intravenous anesthetic for cerebrovascular accident outcomes after surgical revascularization for adult moyamoya disease.
- Post-anesthesia care unit delirium in children with moyamoya disease undergoing indirect revascularization: incidence and risk factors.
- The cerebellar glucose metabolism in moyamoya vasculopathy and its correlation with neurocognitive performance after cerebral revascularization surgery: a [18F]FDG PET study.
- Individualised evaluation based on pathophysiology for moyamoya vasculopathy: application in surgical revascularisation.
- Transient ischemic attack after indirect revascularization surgery for pediatric patients with moyamoya disease: A retrospective study of intraoperative blood pressure.
Trials on ClinicalTrials.gov5
- Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial
- Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Registry of Multicenter Brain-Heart Comorbidity in China
- Neurocognitive and Radiological Assessments in Adult Moyamoya Undergoing Surgery
- The Adult Hemorrhagic Moyamoya Surgery Study
Wilson disease
肝豆状核变性(Wilson 病)Led 1 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (7.5%).
- Open trials led
- 0
- Research papers it led
- 1
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Trials on ClinicalTrials.gov1
Biliary atresia
胆道闭锁Led 21 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.8%).
- Open trials led
- 3
- Research papers it led
- 21
- Trials it led
- 4
- Share of China's trials
- 20.0%
- Share of the world's papers
- 2.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Effect of Adjuvant Steroid Therapy in Type 3 Biliary Atresia: A Single-Center, Open-Label, Randomized Controlled Trial.
- Preventive effect of prophylactic intravenous antibiotics against cholangitis in biliary atresia: a randomized controlled trial.
- Development and validation of a minimally invasive diagnostic model for biliary atresia using artificial intelligence.
- Establishment of Biliary Atresia Prognostic Classification System via Survival-Based Forward Clustering - A New Biliary Atresia Classification.
- Incidence and outcome of biliary atresia in Shanghai, China from 2015 to 2016: a cohort study.
Trials on ClinicalTrials.gov6
- Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
- Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
- High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
- A Peer Support Network System Construction for the Primary Caregivers of Children With Biliary Atresia
- Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy
- An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 3 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Deciphering the molecular landscape of NMDAR-E associated ovarian teratomas: a Multi-Omics approach.
- Brain MRI features of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis secondary to central nervous system infection in adult patients.
- Performance of the clinical assessment scale for autoimmune encephalitis in a pediatric autoimmune encephalitis cohort.
Takayasu arteritis
大动脉炎Led 37 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (24.6%).
- Open trials led
- 2
- Research papers it led
- 37
- Trials it led
- 6
- Share of China's trials
- 24.0%
- Share of the world's papers
- 4.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study.
- Comment on: Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis. Reply.
- PET vascular activity score for predicting new angiographic lesions in patients with Takayasu arteritis: a Chinese cohort study.
- Comment on: A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG-PET/CT: a Chinese cohort study: reply.
- Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study.
Trials on ClinicalTrials.gov6
- A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
- A Pilot Study in Severe Patients With Takayasu Arteritis.
- Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
- Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients
- Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis
- The Registry Study of Takayasu Arteritis in East China
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 18 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 18
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Safety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects.
- Physical activity and idiopathic pulmonary fibrosis: A prospective cohort study in UK Biobank and Mendelian randomization analyses.
- Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume.
- Baicalin inhibits the Akt/mTOR/ULK1 signaling pathway to activate autophagy and ameliorate pulmonary fibrosis.
- Iron dysregulation and ferroptosis are associated with pulmonary fibrosis: Insight from idiopathic pulmonary fibrosis, systemic sclerosis, and COVID-19 patients.
Trials on ClinicalTrials.gov6
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 22 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.3%).
- Open trials led
- 0
- Research papers it led
- 22
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Dysregulation of extracellular potassium distinguishes healthy ageing from neurodegeneration.
- Brain region-specific synaptic function of FUS underlies the FTLD-linked behavioural disinhibition.
- A new ERBB4 variant in amyotrophic lateral sclerosis type 19: Case report and review of the literature.
- Iron quantitative analysis of motor combined with bulbar region in M1 cortex may improve diagnosis performance in ALS.
- Integrated profiling of iPSC-derived motor neurons carrying C9orf72, FUS, TARDBP, or SOD1 mutations.
Trials on ClinicalTrials.gov1
Spinal muscular atrophy
脊髓性肌萎缩症Led 16 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (29.1%).
- Open trials led
- 0
- Research papers it led
- 16
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 2.9%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Teaching NeuroImages: Hirayama Disease With Symmetric Atrophy of Bilateral Distal Upper Extremities.
- Effectiveness and safety of Risdiplam for types 1-3 spinal muscular atrophy in a single center.
- Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China.
- Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.
- The role of leisure-time physical activity in maintaining cervical lordosis after anterior cervical fusion and its impact on the motor function in patients with hirayama disease: a retrospective cohort analysis.
Trials on ClinicalTrials.gov6
- A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA
- Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy
- Adult Spinal Muscular Atrophy (SMA) China Registry
- Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
Fabry disease
法布雷病Led 1 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.3%).
- Open trials led
- 1
- Research papers it led
- 1
- Trials it led
- 2
- Share of China's trials
- 14.3%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Pompe disease
庞贝病Led 1 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.7%).
- Open trials led
- 0
- Research papers it led
- 1
- Trials it led
- 1
- Share of China's trials
- 11.1%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led1
Trials on ClinicalTrials.gov1
Duchenne muscular dystrophy
杜氏肌营养不良Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.8%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Pseudoexon activating by a deep intronic variant and phenotype variation in a Chinese family with dystrophinopathy.
- Comprehensive analysis of 2097 patients with dystrophinopathy based on a database from 2011 to 2021.
- Acute hepatotoxicity of intravenous amiodarone in a Becker muscular dystrophy patient with decompensated heart failing and ABCB4 gene mutation: as assessed for causality using the updated RUCAM.
- Two novel deep intronic variants cause Duchenne muscular dystrophy by splice-altering mechanism.
Trials on ClinicalTrials.gov4
- Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
- Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
- A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy
- Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
Behçet disease
白塞病Led 28 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.9%).
- Open trials led
- 0
- Research papers it led
- 28
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 2.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'.
- Massive lower gastrointestinal bleeding due to rupture of the superior mesenteric artery branch in Behçet's disease: case report.
- Clinical features of cardiac and vascular involvements in Behçet's syndrome: a cross-sectional study from Shanghai Behçet's syndrome database.
- A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well-Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease.
- Autoinflammatory syndromes mimicking Behçet's disease with gastrointestinal involvement: a retrospective analysis.
Trials on ClinicalTrials.gov1
IgA nephropathy
IgA 肾病Led 14 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 0
- Research papers it led
- 14
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Exploring the shared molecular mechanisms of primary hypertension and IgA vasculitis through a case report and combining bioinformatics analysis.
- Serum soluble interleukin-2 receptor alpha may predict tubulointerstitial inflammatory cell infiltration and short-term disease progression in immunoglobin A nephropathy.
- Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study.
- Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.
- IgA nephropathy: gut microbiome regulates the production of hypoglycosilated IgA1 via the TLR4 signaling pathway.
Trials on ClinicalTrials.gov6
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
- A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
- A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
- Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
Osteogenesis imperfecta
成骨不全症Led 2 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Hirschsprung disease
先天性巨结肠Led 4 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.0%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Aberrant high expression of the TET1 gene in Hirschsprung's disease.
- Skip segment Hirschsprung's disease: report of two rare cases and management.
- Serum Metabolomic Signatures of Hirschsprung's Disease Based on GC-MS and LC-MS.
- Intestinal fibrosis in aganglionic segment of Hirschsprung's disease revealed by single-cell RNA sequencing.
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led 5 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.5%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Efficacy and Safety of Dupilumab Monotherapy in Patients With Dystrophic Epidermolysis Bullosa: A Retrospective Study of 8 Cases.
- A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab.
- Staphylococcus aureus Promotes Cutaneous Lesions in Patients With Epidermolysis Bullosa.
- Treatment of epidermolysis bullosa simplex with dupilumab.
- Generation of the induced pluripotent stem cell line (ZSPHARi001-A) from a patient with recessive dystrophic epidermolysis bullosa carrying compound heterozygous mutation in the COL7A1 gene.
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 1 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 1
- Trials it led
- 1
- Share of China's trials
- 33.3%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.